IMRT Usage and Cost Related to Geography And Medicare Reimbursement Policy, Study Finds
Aflibercept Improves Overall Survival In Second-Line Colorectal Cancer Setting
Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint
Beta Blockers Negate Harmful Recurrence Risks of ACE Inhibitors
Study Validates “PEM” Scans As Biopsy Guidance Method
Prostatectomy Lowers Death Risk Compared to Watchful Waiting
Postponed Surgery For Low-Grade Prostate Cancer Adds No Risk
Acupuncture Can Relieve Side Effects of Hormone Treatment
Selumetinib Displays Positive Results, 60% with Stable Disease
National Health Organizations Warn of Risks in Indoor Tanning
Clinical Trials Approved By NCI CTEP Last Month
SWOG Launching New Study Based on Recurrence Test Scores
Centocor Withdraws Yondelis After FDA Calls for New Study
FDA Approves New Device For Glioblastoma Multiforme
EU Gives Marketing Approval For HBV Sequencing Test
Roche Markets CMV Test in Europe
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest
- In the Headlines: MD Anderson’s Pisters on doing “something gigantic for pediatric cancer”
- As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures - In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater - Scaling excellence: How City of Hope is transforming cancer care delivery